Matches in Wikidata for { <http://www.wikidata.org/entity/Q66068066> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- Q66068066 description "clinical trial" @default.
- Q66068066 description "ensayu clínicu" @default.
- Q66068066 description "klinisch onderzoek" @default.
- Q66068066 description "клінічне випробування" @default.
- Q66068066 description "կլինիկական փորձարկում" @default.
- Q66068066 name "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment" @default.
- Q66068066 name "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment" @default.
- Q66068066 type Item @default.
- Q66068066 label "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment" @default.
- Q66068066 label "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment" @default.
- Q66068066 prefLabel "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment" @default.
- Q66068066 prefLabel "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment" @default.
- Q66068066 P1050 Q66068066-FE81CB19-3EC2-4D33-AAB6-F6C0F892662E @default.
- Q66068066 P1132 Q66068066-13232CFC-862A-492F-B8FE-19775219A043 @default.
- Q66068066 P131 Q66068066-5E2DD1B7-AED4-42FB-977D-C167AF54EAD1 @default.
- Q66068066 P1476 Q66068066-C9FD1A07-167D-4FF9-8C05-AE7664F1C314 @default.
- Q66068066 P17 Q66068066-002706C5-AB05-45B9-AE63-5CAD9C16AD8B @default.
- Q66068066 P17 Q66068066-10A70CB6-065F-47D8-9BFE-3872AAFE6EF0 @default.
- Q66068066 P17 Q66068066-2F74A106-C0B0-4FA7-ABDC-DB7D8F975EA6 @default.
- Q66068066 P17 Q66068066-4E049896-AD71-45EC-882A-8110A5FD94B1 @default.
- Q66068066 P17 Q66068066-56CDA08B-EED2-449A-80BB-D628CB034115 @default.
- Q66068066 P17 Q66068066-66B9FD12-8C87-41ED-94AD-5798AABDD948 @default.
- Q66068066 P17 Q66068066-759FB6DA-1E88-4926-B7F4-F2ECFE116E2E @default.
- Q66068066 P17 Q66068066-B4DD6818-D686-448A-9DE3-FD93AB9D6214 @default.
- Q66068066 P17 Q66068066-B4EFF72F-6EEF-4A79-85E3-A1567C605001 @default.
- Q66068066 P17 Q66068066-BD6EAA58-91EF-4BD7-B515-8D28C628D52F @default.
- Q66068066 P17 Q66068066-C6FC0046-CE33-4FE4-91B7-6890E3C90FA7 @default.
- Q66068066 P17 Q66068066-CB3FD992-A442-448C-B4B5-1F254932D447 @default.
- Q66068066 P17 Q66068066-FB44B49D-510D-4DF3-ABE1-549C5B8A837B @default.
- Q66068066 P1813 Q66068066-A17EF60A-E5DD-4881-BE55-CB93844264C3 @default.
- Q66068066 P2899 Q66068066-73BA5326-E421-4563-9A87-931185C6CAAA @default.
- Q66068066 P3098 Q66068066-12B20FB0-85CD-4E12-BA09-63C3A0500FD1 @default.
- Q66068066 P31 Q66068066-FB730F00-E384-4CE4-8ADE-2AC25C51E69C @default.
- Q66068066 P4135 Q66068066-54CC48B1-541F-4515-B29F-334DB80662F5 @default.
- Q66068066 P4844 Q66068066-A1CBC830-4AD3-49D6-8B62-B54A8F3B60B7 @default.
- Q66068066 P580 Q66068066-6D3B9791-FCE6-49B2-B465-6E5D187847EB @default.
- Q66068066 P582 Q66068066-F621066B-2998-48AB-867F-58E1B199C7EE @default.
- Q66068066 P6099 Q66068066-2E0CF950-58B0-4D58-8183-54BC052FA5F6 @default.
- Q66068066 P8363 Q66068066-2E289D17-1045-4B01-B7D3-BE22EC4EE5DC @default.
- Q66068066 P1050 Q33525 @default.
- Q66068066 P1132 "+888" @default.
- Q66068066 P131 Q8646 @default.
- Q66068066 P1476 "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation" @default.
- Q66068066 P17 Q142 @default.
- Q66068066 P17 Q155 @default.
- Q66068066 P17 Q16 @default.
- Q66068066 P17 Q17 @default.
- Q66068066 P17 Q183 @default.
- Q66068066 P17 Q30 @default.
- Q66068066 P17 Q38 @default.
- Q66068066 P17 Q40 @default.
- Q66068066 P17 Q408 @default.
- Q66068066 P17 Q419 @default.
- Q66068066 P17 Q43 @default.
- Q66068066 P17 Q865 @default.
- Q66068066 P17 Q869 @default.
- Q66068066 P1813 "EMERALD-2" @default.
- Q66068066 P2899 "+18" @default.
- Q66068066 P3098 "NCT03847428" @default.
- Q66068066 P31 Q30612 @default.
- Q66068066 P4135 "+150" @default.
- Q66068066 P4844 Q413299 @default.
- Q66068066 P580 "2019-04-29T00:00:00Z" @default.
- Q66068066 P582 "2022-06-29T00:00:00Z" @default.
- Q66068066 P6099 Q42824827 @default.
- Q66068066 P8363 Q78089383 @default.